MARKET

CRVO

CRVO

CervoMed
NASDAQ
9.98
+0.83
+9.07%
After Hours: 9.75 -0.23 -2.30% 19:40 04/01 EDT
OPEN
9.00
PREV CLOSE
9.15
HIGH
10.80
LOW
8.64
VOLUME
803.65K
TURNOVER
--
52 WEEK HIGH
25.92
52 WEEK LOW
1.800
MARKET CAP
86.85M
P/E (TTM)
-4.9457
1D
5D
1M
3M
1Y
5Y
1D
EXCLUSIVE: March's 20 Most-Searched Tickers On Benzinga Pro — Where Do Tesla, Nvidia, Apple, Applovin Stock Rank?
Benzinga · 3h ago
Biotech Stocks Q1 2025 Recap: Winners And Underperformers
Seeking Alpha · 1d ago
Weekly Report: what happened at CRVO last week (0324-0328)?
Weekly Report · 1d ago
12 Health Care Stocks Moving In Thursday's Intraday Session
Benzinga · 5d ago
12 Health Care Stocks Moving In Wednesday's Intraday Session
Benzinga · 6d ago
CervoMed Is Maintained at Buy by D. Boral Capital
Dow Jones · 6d ago
Tuesday Sector Laggards: Biotechnology, Computers
NASDAQ · 03/25 16:34
CERVOMED ANNOUNCES ORAL PRESENTATION AT 19TH INTERNATIONAL CONFERENCE ON ALZHEIMER’S AND PARKINSON’S DISEASES AND RELATED NEUROLOGIC DISORDERS (AP/PD™)
Reuters · 03/25 12:00
More
About CRVO
More
CervoMed Inc. is a clinical-stage biotechnology company focused on developing treatments for age-related neurologic disorders. It is focused on the development of its lead drug candidate, neflamapimod, an investigational, orally administered, small molecule brain penetrant that inhibits p38a in the neurons (nerve cells) within the brains of people with neurodegenerative diseases. Its neflamapimod is in clinical development as a disease-modifying treatment for neurodegenerative diseases, such as dementia with Lewy Bodies and early Alzheimer’s disease. In addition, pre-clinical data supports the potential role of neflamapimod in recovery after stroke. Neflamapimod has the potential to treat and improve synaptic dysfunction, the reversible aspect of the underlying disease processes in dementia with Lewy bodies (DLB) and certain other neurological disorders. It is being evaluated in its ongoing RewinD-LB Trial, a Phase 2b study in patients with DLB.
Recently
Symbol
Price
%Change

Webull offers CervoMed Inc stock information, including NASDAQ: CRVO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CRVO stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading CRVO stock methods without spending real money on the virtual paper trading platform.